J. Andres Suarez-Londono, MD, NYU Langone Health, New York City, NY, discusses the rationale and results of a Phase Ib/II study of post-transplant cyclophosphamide (PTCy), abatacept and short course of tacrolimus (CAST) for the prevention of graft-versus-host disease (GvHD) following haploidentical peripheral blood stem cell transplantation (PBSCT; NCT04503616). Dr Suarez-Londono explains that a high percentage of the patients enrolled in this study were from racial or ethnic minorities. The primary endpoint was the incidence of grade 2-4 acute GvHD at day 120 and was 17.4%. Only two patients developed grade 3-4 acute GvHD. In addition, none of the patients that received the full dose of abatacept developed grade 3-4 acute GvHD. Moderate to severe chronic GvHD was seen in 13.4% of patients. The study reported adverse events including CMV and EBV reactivation, thrombotic microangiopathy (TMA), and sinusoidal obstruction syndrome (SOS). Overall, CAST appeared to be an effective and well-tolerated regimen for the prevention of GvHD following haploidentical transplantation. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
